Pharmacology of Induced Artificial Platelets in Regenerative Medicine: Beyond Transfusion

    December 2025 in “ International Journal of Pharmacology ”
    Kyuyeon null Choe, Chihwa null Kim, Hyo-Jin null Jeon, S Han
    New to Platelet-Rich Plasma? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This review highlights that iPSC-derived artificial platelets offer a promising alternative to platelet-rich plasma for regenerative medicine, with standardized manufacturing and reproducible pharmacological properties, addressing variability issues associated with donor-derived platelets and showing therapeutic potential in preclinical models of osteoarthritis.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    Induced pluripotent stem cell (iPSC)-derived artificial platelets offer a promising advancement in regenerative medicine by overcoming the limitations of platelet-rich plasma therapies, such as batch variability and inconsistent outcomes. These artificial platelets are produced under standardized, scalable conditions, ensuring precise control over their composition and function. Preclinical studies have shown their therapeutic efficacy in osteoarthritis models, and emerging clinical data indicate acceptable safety profiles. This shift from transfusion-focused applications to regenerative medicine necessitates new pharmacological characterization frameworks, highlighting the potential of iPSC-derived artificial platelets in providing consistent and effective regenerative therapies.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results